FindTrial
Sign In

An Open-label, Multi-centre, Drug-drug Interaction Study to Assess the Effect of Voglibose (0.2mg Tid) on the Pharmacokinetics, Safety and Tolerability of Single Oral Administration of Dapagliflozin (10mg) in Japanese Patients With Type 2 Diabetes

An Open-label, Multi-centre, Drug-drug Interaction Study to Assess the Effect of Voglibose (0.2mg Tid) on the Pharmacokinetics, Safety and Tolerability of Single Oral Administration of Dapagliflozin (10mg) in Japanese Patients With Type 2 Diabetes

Status
Unknown
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221000
Enrollment
Unknown
Registered
2010-02-10
Start date
2010-02-10
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Interventions

investigational material(s) Generic name etc : Dapagliflozin INN of investigational material : Therapeutic category code : 396 Antidiabetic agents Dosage and Administration for Investigational materi

Sponsors

AstraZeneca
Lead Sponsor
Bristol-Myers Squibb
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Already on voglibose treatment with a steady dosage for at least 8 weeks - Provision of informed consent prior to any study specific procedures - Diagnosed with type 2 diabetes

Exclusion criteria

Exclusion criteria: - Having clinically relevant medical history or concurrent disease such as cardiovascular disease, renal disease, retinopathy, hepatic disease and haematological disease. - The investigator(s) judged that the Subject should not participate in the study according to screening test or medical history.

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026